Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells

Molecular Pharmaceutics

Volumn 8, Issue 2, 2011, Pages 375-386

  Ai, Shibin ^a   Duan, Jianli ^a   Liu, Xin ^a   Bock, Stephanie ^a   Tian, Yuan ^b   Huang, Zebo ^a  

^a WUHAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

doxorubicin; drug delivery; epidermal growth factor receptor; peptide

Indexed keywords

BINDING PROTEIN; CYSTEINYLMETHIONYLTYROSYLISOLEUCYLGLUTAMYLALANYLLEUCYLASPARTYLLYSYLTYROSYLALANYLCYSTEINAMIDE CARBOXYLIC ACID; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTER; GLUTARIC ACID; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASMS; PEPTIDE FRAGMENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953814373     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100243j     Document Type: Article

References (53)

1. Gewirtz, D. A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57, 727-741.
2. Lal, S.; Mahajan, A.; Chen, W. N.; Chowbay, B. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr. Drug Metab. 2010, 11, 115-128.
3. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56, 185-229.
4. Thornton, K. Chemotherapeutic management of soft tissue sarcoma. Surg. Clin. North Am. 2008, 88, 647-660.
5. Raschi, E.; Vasina, V.; Ursino, M. G.; Boriani, G.; Martoni, A.; De Ponti, F. Anticancer drugs and cardiotoxiciy: Insights and perspectives in the era of targeted therapy. Pharmacol. Ther. 2010, 125, 196-218.
6. Mordente, A.; Meucci, E.; Silvestrini, A.; Martorana, G. E.; Giardina, B. New developments in anthracycline-induced cardiotoxicity. Curr. Med. Chem. 2009, 16, 1656-1672.
7. Ferreira, A. L.; Matsubara, L. S.; Matsubara, B. B. Anthracycline-induced cardiotoxicity. Cardiovasc. Hematol. Agents Med. Chem. 2008, 6, 278-281.
8. Langer, M.; Kratz, F.; Rothen-Rutishauser, B.; Wunderli-Allenspach, H.; Beck-Sickinger, A. G. Novel peptide conjugates for tumor-specific chemotherapy. J. Med. Chem. 2001, 44, 1341-1348.
9. Nagy, A.; Schally, A. V. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancer. Biol. Reprod. 2005, 73, 851-859.
10. de Groot, F. M.; Broxterman, H. J.; Adams, H. P.; van Vliet, A.; Tesser, G. I.; Elderkamp, Y. W.; Schraa, A. J.; Kok, R. J.; Molema, G.; Pinedo, H. M.; Scheeren, H. W. Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug. Mol. Cancer Ther. 2002, 1, 901-911.
11. Qian, Z. M.; Li, H.; Sun, H.; Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 2002, 54, 561-587.
12. Schally, A. V.; Nagy, A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci. 2003, 72, 2305-2320. (Pubitemid 36287676)
13. van Hensbergen, Y.; Broxterman, H. J.; Elderkamp, Y. W.; Lankelma, J.; Beers, J. C.; Heijn, M.; Boven, E.; Hoekman, K.; Pinedo, H. M. A doxorubicin-CNGRC conjugate with prodrug properties. Biochem. Pharmacol. 2002, 63, 897-908.
14. Emons, G.; Sindermann, H.; Engel, J.; Schally, A. V.; Gründker, C. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology 2009, 90, 15-18.
15. Dutta, P. R.; Maity, A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett. 2007, 254, 165-177. (Pubitemid 47161103)
16. Herbst, R. S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59, 21-26.
17. Harari, P. M.; Allen, G. W.; Bonner, J. A. Biology of interactions: antiepidermal growth factor receptor agents. J. Clin. Oncol. 2007, 25, 4057-4065.
18. Okamoto, I. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS. J. 2010, 277, 309-315.
19. Schneider, M. R.; Wolf, E. The epidermal growth factor receptor ligands at a glance. J. Cell Physiol. 2009, 218, 460-466.
20. Cooke, R. M.; Wilkinson, A. J.; Baron, M.; Pastore, A.; Tappin, M. J.; Campbell, I. D.; Gregory, H.; Sheard, B. The solution structure of human epidermal growth factor. Nature 1987, 327, 339-341.
21. Montelione, G. T.; Wüthrich, K.; Nice, E. C.; Burgess, A. W.; Scheraga, H. A. Solution structure of murine epidermal growth factor: determination of the polypeptide backbone chain-fold by nuclear magnetic resonance and distance geometry. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 5226-5230.
22. Koide, H.; Muto, Y.; Kasai, H.; Kohri, K.; Hoshi, K.; Takahashi, S.; Tsukumo, K.; Sasaki, T.; Oka, T.; Miyake, T. A site-directed mutagenesis study on the role of isoleucine-23 of human epidermal growth factor in the receptor binding. Biochim. Biophys. Acta 1992, 1120, 257-261.
23. Wingens, M.; Walma, T.; van Ingen, H.; Stortelers, C.; van Leeuwen, J. E.; van Zoelen, E. J.; Vuister, G. W. Structural analysis of an epidermal growth factor/transforming growth factor-alpha chimera with unique ErbB binding specificity. J. Biol. Chem. 2003, 278, 39114-39123.
24. Ogiso, H.; Ishitani, R.; Nureki, O.; Fukai, S.; Yamanaka, M.; Kim, J. H.; Saito, K.; Sakamoto, A.; Inoue, M.; Shirouzu, M.; Yokoyama, S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110, 775-787. (Pubitemid 35291060)
25. Komoriya, A.; Hortsch, M.; Meyers, C.; Smith, M.; Kanety, H.; Schlessinger, J. Biologically active synthetic fragments of epidermal growth factor: localization of a major receptor-binding region. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 1351-1355.
26. Wilson, C. L.; Monteith, W. B.; Danell, A. S.; Burns, C. S. Purification and characterization of the central segment of prothymosin-alpha: methodology for handling highly acidic peptides. J. Pept. Sci. 2006, 12, 721-725.
27. Nagy, A.; Schally, A. V.; Armatis, P.; Szepeshazi, K.; Halmos, G.; Kovacs, M.; Zarandi, M.; Groot, K.; Miyazaki, M.; Jungwirth, A.; Horvath, J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 7269-7273.
28. Chen, Q.; Sowa, D. A.; Gabathuler, R. Synthesis of doxorubicin conjugates through 14-hydroxy group to melanotransferrin P97. Synth. Commun. 2003, 33, 2389-2398.
29. Bai, L.; Zhu, R.; Chen, Z.; Gao, L.; Zhang, X.; Wang, X.; Bai, C. Potential role of short hairpin RNA targeting epidermal growth factor receptor in growth and sensitivity to drugs of human lung adenocarcinoma cells. Biochem. Pharmacol. 2006, 71, 1265-1271.
30. Bidwell, G. L., 3rd.; Davis, A. N.; Fokt, I.; Priebe, W.; Raucher, D. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance. Invest. New Drugs 2007, 25, 313-326. (Pubitemid 46944856)
31. Overholser, J. P.; Prewett, M. C.; Hooper, A. T.; Waksal, H. W.; Hicklin, D. J. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000, 89, 74-82. (Pubitemid 30451276)
32. Abbosh, P. H.; Montgomery, J. S.; Starkey, J. A.; Novotny, M.; Zuhowski, E. G.; Egorin, M. J.; Moseman, A. P.; Golas, A.; Brannon, K. M.; Balch, C.; Huang, T. H.; Nephew, K. P. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res. 2006, 66, 5582-5591. (Pubitemid 43927108)
33. Pang, Z.; Feng, L.; Hua, R.; Chen, J.; Gao, H.; Pan, S.; Jiang, X.; Zhang, P. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol. Pharmaceutics 2010, 7, 1995-2005.
34. Cao, N.; Feng, S. S. Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials 2008, 29, 3856-3865.
35. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63. (Pubitemid 14203433)
36. Han, L.; Wang, W.; Fang, Y.; Feng, Z.; Liao, S.; Li, W.; Li, Y.; Li, C.; Maitituoheti, M.; Dong, H.; Lai, W.; Gao, Q.; Xi, L.; Wu, M.; Wang, D.; Zhou, J.; Meng, L.; Wang, S.; Ma, D. Soluble B and T lymphocyte attenuator possesses antitumor effects and facilitates heat shock protein 70 vaccine-triggered antitumor immunity against a murine TC-1 cervical cancer model in vivo. J. Immunol. 2009, 183, 7842-7850.
37. Mamot, C.; Drummond, D. C.; Noble, C. O.; Kallab, V.; Guo, Z.; Hong, K.; Kirpotin, D. B.; Park, J. W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005, 65, 11631-11638. (Pubitemid 41821723)
38. Etrych, T.; Chytil, P.; Mrkvan, T.; Sírová, M.; Ríhová, B.; Ulbrich, K. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting. J. Controlled Release 2008, 132, 184-192.
39. Al-Abd, A. M.; Kim, N. H.; Song, S. C.; Lee, S. J.; Kuh, H. J. A simple HPLC method for doxorubicin in plasma and tissues of nude mice. Arch. Pharm. Res. 2009, 32, 605-611.
40. Wu, G.; Barth, R. F.; Yang, W.; Kawabata, S.; Zhang, L.; Green-Church, K. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. 2006, 5, 52-59.
41. Goldstein, N. I.; Prewett, M.; Zuklys, K.; Rockwell, P.; Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1995, 1, 1311-1318.
42. Pohl, M.; Stricker, I.; Schoeneck, A.; Schulmann, K.; Klein-Scory, S.; Schwarte-Waldhoff, V.; Hasmann, M.; Tannapfel, A.; Schmiegel, W.; Reinacher-Schick, A. Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. J. Cancer Res. Clin. Oncol. 2009, 135, 1377-1386.
43. Liao, X.; Che, X.; Zhao, W.; Zhang, D.; Long, H.; Prakash, C.; Li, H. Effects of propranolol in combination with radiation on apoptosis and survival of gastric cancer cells in vitro. Radiat. Oncol. 2010, 5, 58.
44. Ueno, Y.; Sakurai, H.; Tsunoda, S.; Choo, M. K.; Matsuo, M.; Koizumi, K.; Saiki, I. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int. J. Cancer 2008, 123, 340-347. (Pubitemid 351842018)
45. Hirsch, D. S.; Shen, Y.; Wu, W. J. Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42. Cancer Res. 2006, 66, 3523-3523.
46. Lurje, G.; Lenz, H. J. EGFR signaling and drug discovery. Oncology 2009, 77, 400-410.
47. Mitsudomi, T.; Yatabe, Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS. J. 2010, 277, 301-308.
48. Meyer-Losic, F.; Quinonero, J.; Dubois, V.; Alluis, B.; Dechambre, M.; Michel, M.; Cailler, F.; Fernandez, A. M.; Trouet, A.; Kearsey, J. Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell). J. Med. Chem. 2006, 49, 6908-6916. (Pubitemid 44749756)
49. Halmos, G.; Nagy, A.; Lamharzi, N.; Schally, A. V. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. Cancer Lett. 1999, 136, 129-136. (Pubitemid 29164387)
50. Liang, J. F.; Yang, V. C. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg. Med. Chem. Lett. 2005, 15, 5071-5075.
51. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
52. Szepeshazi, K.; Schally, A. V.; Halmos, G. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy. Int. J. Oncol. 2007, 30, 1485-1492.
53. Wu, W.; Luo, Y.; Sun, C.; Liu, Y.; Kuo, P.; Varga, J.; Xiang, R.; Reisfeld, R.; Janda, K. D.; Edgington, T. S.; Liu, C. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res. 2006, 66, 970-980. (Pubitemid 43165965)